TY - JOUR
T1 - Respiratory syncytial virus infection in adults
AU - Nam, Hannah H.
AU - Ison, Michael G.
N1 - Publisher Copyright:
© Published by the BMJ Publishing Group Limited.
PY - 2019/9/10
Y1 - 2019/9/10
N2 - Human respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is a negative sense, single stranded RNA virus that results in epidemics of respiratory infections that typically peak in the winter in temperate climates and during the rainy season in tropical climates. Generally, one of the two genotypes (A and B) predominates in a single season, alternating annually, although regional variation occurs. RSV is a cause of disease and death in children, older people, and immunocompromised patients, and its clinical effect on adults admitted to hospital is clarified with expanded use of multiplex molecular assays. Among adults, RSV produces a wide range of clinical symptoms including upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease. Here we discuss the latest evidence on the burden of RSV related disease in adults, especially in those with immunocompromise or other comorbidities. We review current therapeutic and prevention options, as well as those in development.
AB - Human respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is a negative sense, single stranded RNA virus that results in epidemics of respiratory infections that typically peak in the winter in temperate climates and during the rainy season in tropical climates. Generally, one of the two genotypes (A and B) predominates in a single season, alternating annually, although regional variation occurs. RSV is a cause of disease and death in children, older people, and immunocompromised patients, and its clinical effect on adults admitted to hospital is clarified with expanded use of multiplex molecular assays. Among adults, RSV produces a wide range of clinical symptoms including upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease. Here we discuss the latest evidence on the burden of RSV related disease in adults, especially in those with immunocompromise or other comorbidities. We review current therapeutic and prevention options, as well as those in development.
UR - http://www.scopus.com/inward/record.url?scp=85072015699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072015699&partnerID=8YFLogxK
U2 - 10.1136/bmj.l5021
DO - 10.1136/bmj.l5021
M3 - Review article
C2 - 31506273
AN - SCOPUS:85072015699
VL - 366
JO - British Medical Journal
JF - British Medical Journal
SN - 0959-8146
M1 - l5021
ER -